Our research focuses on discovering biomarkers for diagnosis, prognosis, and targeted therapy for primary graft dysfunction, acute rejection, and chronic allograft dysfunction after heart and lung transplantation. In order to improve quality of life and patient survival, we must be able to predict, which transplants are doomed to be lost and which recipients will face an untimely death. We aim to establish biomarkers for transplant dysfunction and the side effects of immunosuppressive drugs based on peripheral blood samples and transplant biopsies and employing both classical pathology and new precision medicine tools integrated with electronic health records and eHealth. Moreover, to address the unmet need for heart and lung transplants, we will develop treatment algorithms for the utilization of marginal donors and organs from non-heart beating donors for heart and lung transplantation.